Clinical trial
A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis
NCT00002169 · Agouron Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00002169 |
|---|---|
| Title | A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis |
| Official title | A Phase II, Randomized, Placebo-Controlled Study to Determine the Effects of Viracept on the Clinical Outcome of Cytomegalovirus (CMV) Retinitis in AIDS Patients Who Are Receiving Standard Induction and Maintenance Therapy for This Infection |
| Lead sponsor | Agouron Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cytomegalovirus Retinitis, HIV Infections |
| Intervention type | Drug |
| Interventions | Nelfinavir mesylate |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: